Pipeline
Wholly Owned
Contact us to learn more about out-licensing our assets.
Disease Area (Target)
Discovery
Optimization
IND Enabling
Phase 1
Immunology (TYK2)
Immunology (RIPK2)
Oncology (Undisclosed)
Oncology (Undisclosed)
Immunology (Undisclosed)
Immunology (Undisclosed)